Search

Blogs

Tagged Content List
  • Blog Post: 150 to Go and A Special Piece from Rep. Jean Schmidt

    Advocates across the country are already working with renewed passion to get the remaining Promise meetings scheduled in 2012. As of this afternoon, 26 meetings have been scheduled during the month of January, bringing our grand total to 286. This means that we have met and surpassed yet another crucial...
  • Blog Post: After the Guidance – What Happens Now?

    Happy New Year! I know many of you have been following developments with the artificial pancreas guidance from FDA, so I wanted to give you an update about what’s been going on. After FDA released the artificial pancreas draft guidance document on December 1st our initial review was that the guidance...
  • Blog Post: A New Promise for the Special Diabetes Program

    2011 was an exciting year for JDRF Advocacy, especially with the Promise to Remember Me Campaign ! The year saw the completion of 260 meetings with Members of Congress, which we could not have done without advocates like you. However, we still have another 4 months left of the Campaign. The meeting total...
  • Blog Post: Would you talk to T1D?

    Last week, we told you that currently 85% of people with T1D are adults and this little piece of information generated lots of great feedback from you all. Many of the comments were hopeful and others, about the obstacles you face while beating T1D every day of your life. (Again, I want to thank you...
  • Blog Post: We're Back! Your New Years Promise Digest

    The holidays are over, so that means it is time to hit the ground running again for the Promise Campaign! We have 271 meetings, and still another week and a half left of recess. I am excited to see what our total will be for this month now that the craziness of the holiday season is done! We will be...
  • Blog Post: 85% T1Ds Are Adults…

    Yesterday, our JDRF Advocacy page on Facebook posted a little factoid, ‘…currently, adults make up approximately 85% of those living with type 1 diabetes,’ and then we asked, ‘Are you a T1D adult, T1D teen, or a parent of a T1D? We'd love to know what you think and how T1D...
  • Blog Post: Artificial Pancreas Thanks to Congress

    Today, you can help diabetes advocacy efforts by thanking your Members of Congress while JDRF staff and other experts review the intricate details of the artificial pancreas guidance that was published on December 1. We remain encouraged by the draft guidance thus far and hope you are too! We would not...
  • Blog Post: Thank the FDA and Pass it on!

    Thanks to all your efforts, last week the FDA put out encouraging draft artificial pancreas guidance . While a detailed review is still under way, the FDA draft appears to lay a foundation for accelerating the development and availability of artificial pancreas systems that will improve the lives of...
  • Blog Post: Artificial Pancreas: FDA Releases Guidance

    In the past several weeks over 110,000 diabetes advocates signed onto a petition asking the FDA to issue draft guidance by December 1 that would advance the testing and development of artificial pancreas systems. We wanted to share the news that FDA has just published this important draft guidance and...
Page 1 of 33 (825 items) 12345»

ABOUT JUVENATION
Juvenation is a vibrant social network created especially for and by people with type 1 diabetes and their loved ones. More about Juvenation

Terms of Service | Privacy Policy

DONATION
Please consider making a donation to JDRF to support research toward better treatments and a cure for type 1 diabetes.

SUPPORT
For help on Juvenation you can view answers to common support questions or contact us.


JDRF is the worldwide leader for research to prevent, better treat, and ultimately cure type 1 diabetes. It sets the global agenda for diabetes research, and is the largest charitable funder and advocate of diabetes science worldwide. More about JDRF Juvenation is funded through an educational grant from Novo Nordisk through its Changing Diabetes© leadership initiative. More about Novo Nordisk